661 Dipeptidyl peptidase-9 (DPP9) overexpression is a potential response-predictive biomarker of BXCL701 and pembrolizumab combination treatment in mCRPC patients with SCNC phenotype

Detaylı Bibliyografya
Asıl Yazarlar:	Vincent O’Neill, Veena Agarwal, Moses K Donkor, Sherry Kupchick, Rashmi Deshpande, Dawn Newmin
Materyal Türü:	Makale
Dil:	English
Baskı/Yayın Bilgisi:	BMJ Publishing Group 2023-11-01
Seri Bilgileri:	Journal for ImmunoTherapy of Cancer

1478 Dipeptidyl peptidase 4 (DPP4) inhibition is not solely responsible for the anti-tumor effects of BXCL701, an inhibitor of multiple DPPs, in a murine model of pancreatic ductal adenocarcinoma
Yazar:: Vincent O’Neill, ve diğerleri
Baskı/Yayın Bilgisi: (2023-11-01)

341 Phase 1b/2 study of BXCL701, an oral activator of the systemic innate immunity pathway, combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC)
Yazar:: Lawrence Karsh, ve diğerleri
Baskı/Yayın Bilgisi: (2020-11-01)

382 Targeting innate immunity with BXCL701 in combination with pembrolizumab in patients with advanced solid cancers: phase 2 basket study
Yazar:: Filip Janku, ve diğerleri
Baskı/Yayın Bilgisi: (2020-11-01)

Management of elderly mCRPC patients
Yazar:: Seiichiro Ozono
Baskı/Yayın Bilgisi: (2015-12-01)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
Yazar:: Chenkai Cui, ve diğerleri
Baskı/Yayın Bilgisi: (2022-09-01)

Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology
Yazar:: Alba Sebastián-Martín, ve diğerleri
Baskı/Yayın Bilgisi: (2022-08-01)

Withdrawal syndrome and PSA flare in the management of mCRPC with abiraterone
Yazar:: Po Hui Chiang
Baskı/Yayın Bilgisi: (2015-12-01)

Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives
Yazar:: H. Taghizadeh, ve diğerleri
Baskı/Yayın Bilgisi: (2019-11-01)

Effects of Inhibiting Dipeptidyl Peptidase-4 (DPP4) in Cows with Subclinical Ketosis.
Yazar:: Kirsten Schulz, ve diğerleri
Baskı/Yayın Bilgisi: (2015-01-01)

Identification of Dipeptidyl-Peptidase (DPP)5 and DPP7 in Porphyromonas endodontalis, Distinct from Those in Porphyromonas gingivalis.
Yazar:: Haruka Nishimata, ve diğerleri
Baskı/Yayın Bilgisi: (2014-01-01)

The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
Yazar:: Tianli Zhang, ve diğerleri
Baskı/Yayın Bilgisi: (2021-12-01)

Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)
Yazar:: Douglas G McNeel, ve diğerleri
Baskı/Yayın Bilgisi: (2022-03-01)

Inhibition of dipeptidyl peptidase IV (DPP-IV) by proline containing casein-derived peptides
Yazar:: Alice B. Nongonierma, ve diğerleri
Baskı/Yayın Bilgisi: (2013-10-01)

344 Phase 3 trial of pembrolizumab and enzalutamide versus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) (KEYNOTE-641)
Yazar:: Arnulf Stenzl, ve diğerleri
Baskı/Yayın Bilgisi: (2020-11-01)

Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging Trends
Yazar:: Thapa B, ve diğerleri
Baskı/Yayın Bilgisi: (2024-09-01)

Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Yazar:: Iván Henríquez, ve diğerleri
Baskı/Yayın Bilgisi: (2021-09-01)

Dipeptidyl Peptidase 4 (DPP4) as A Novel Adipokine: Role in Metabolism and Fat Homeostasis
Yazar:: Ilaria Barchetta, ve diğerleri
Baskı/Yayın Bilgisi: (2022-09-01)

Evaluation of the potential of dietary proteins as precursors of dipeptidyl peptidase (DPP)-IV inhibitors by an in silico approach
Yazar:: Isabelle M.E. Lacroix, ve diğerleri
Baskı/Yayın Bilgisi: (2012-04-01)

Treatment response assessment in mCRPC: is PSMA-PET/CT going to take the lead?
Yazar:: Martina Di Franco, ve diğerleri
Baskı/Yayın Bilgisi: (2024-10-01)

Homologous Recombination Repair Testing Patterns and Outcomes in mCRPC by Alteration Status and Race
Yazar:: Bilen MA, ve diğerleri
Baskı/Yayın Bilgisi: (2024-09-01)

PROpel trial: Are PARP inhibitors ready to become the first-line treatment for mCRPC?
Yazar:: Abhay Singh Gaur
Baskı/Yayın Bilgisi: (2022-01-01)

A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4
Yazar:: Takehiro Yamaguchi, ve diğerleri
Baskı/Yayın Bilgisi: (2019-02-01)

Identification and dipeptidyl peptidase IV (DPP-IV) inhibitory activity verification of peptides from mouse lymphocytes
Yazar:: Juan Wang, ve diğerleri
Baskı/Yayın Bilgisi: (2022-11-01)

Elevated Dipeptidyl Peptidase IV (DPP-IV) Activity in Plasma from Patients with Various Lysosomal Diseases
Yazar:: Agnieszka Ługowska, ve diğerleri
Baskı/Yayın Bilgisi: (2021-02-01)

Dipeptidyl peptidase IV (DPP-IV) inhibitory properties of camel milk protein hydrolysates generated with trypsin
Yazar:: Alice B. Nongonierma, ve diğerleri
Baskı/Yayın Bilgisi: (2017-07-01)

Rapid Identification of Dipeptidyl Peptidase-IV (DPP-IV) Inhibitory Peptides from Ruditapes philippinarum Hydrolysate
Yazar:: Rui Liu, ve diğerleri
Baskı/Yayın Bilgisi: (2017-10-01)

Natural Compounds and Histone Deacetylase Inhibitors: A Combined Approach Against mCRPC Cells
Yazar:: Janiah Alimudin, ve diğerleri
Baskı/Yayın Bilgisi: (2025-01-01)

Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model
Yazar:: Nourridine Siewe, ve diğerleri
Baskı/Yayın Bilgisi: (2022-01-01)

Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model.
Yazar:: Nourridine Siewe, ve diğerleri
Baskı/Yayın Bilgisi: (2022-01-01)

The Many Faces Of mCRPC- Assessing Patient Profiles and Tailoring Treatment in a Changing Landscape
Yazar:: Manfred Wirth, ve diğerleri
Baskı/Yayın Bilgisi: (2014-05-01)

Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients With mCRPC Treated With Abiraterone
Yazar:: Cristian Lolli, ve diğerleri
Baskı/Yayın Bilgisi: (2016-10-01)

Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A updated results
Yazar:: J.M. Piulats, ve diğerleri
Baskı/Yayın Bilgisi: (2020-07-01)

Identification of dipeptidyl-peptidase 4 (DPP-4) inhibitors from miracle berry fruit (Synsepalum dulcificum) extract
Yazar:: Hamsah Zollapi, Nuraliana Najwa, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

The multiple actions of dipeptidyl peptidase 4 (DPP-4) and its pharmacological inhibition on bone metabolism: a review
Yazar:: L. M. Pechmann, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

Identification of Dipeptidyl Peptidase (DPP) Family Genes in Clinical Breast Cancer Patients via an Integrated Bioinformatics Approach
Yazar:: Tak-Kee Choy, ve diğerleri
Baskı/Yayın Bilgisi: (2021-07-01)

Dipeptidyl Amino-Peptidase 3 (DPP3) as an Early Marker of Severity in a Patient Population with Cardiogenic Shock
Yazar:: Pasquale Innelli, ve diğerleri
Baskı/Yayın Bilgisi: (2023-04-01)

KEYNOTE-365 cohort c updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients with metastatic Castration-Resistant Prostate Cancer (mCRPC)
Yazar:: S. Feyerabend, ve diğerleri
Baskı/Yayın Bilgisi: (2020-07-01)

Breaking through resistance in mCRPC: Enzalutamide analogues as effective anticancer agents for enhanced male survival
Yazar:: Ritesh P. Bhole, ve diğerleri
Baskı/Yayın Bilgisi: (2023-12-01)

Association between the Immunophenotype of Peripheral Blood from mCRPC Patients and the Outcomes of Radium-223 Treatment
Yazar:: Elisabet Cantó, ve diğerleri
Baskı/Yayın Bilgisi: (2023-06-01)

Dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin ameliorates inflammation and autophagy in mice hindlimb ischemia–reperfusion injury
Yazar:: Marwa Abdeltawab Mohammed, ve diğerleri
Baskı/Yayın Bilgisi: (2024-12-01)

661 Dipeptidyl peptidase-9 (DPP9) overexpression is a potential response-predictive biomarker of BXCL701 and pembrolizumab combination treatment in mCRPC patients with SCNC phenotype

Benzer Materyaller

Benzer Materyaller